References
- Bando, T. and Sugiyama, H. (2006). Synthesis and biological properties of sequence-specific DNA-alkylating pyrrole-imidazole polyamides. Acc. Chem. Res. 39, 935-944. https://doi.org/10.1021/ar030287f
- Best, T.P., Edelson, B.S., Nickols, N.G., and Dervan, P.B. (2003). Nuclear localization of pyrrole-imidazole polyamide-fluorescein conjugates in cell culture. Proc. Natl. Acad. Sci. U. S. A. 100, 12063-12068. https://doi.org/10.1073/pnas.2035074100
- Goyama, S., Schibler, J., Cunningham, L., Zhang, Y., Rao, Y., Nishimoto, N., Nakagawa, M., Olsson, A., Wunderlich, M., Link, K.A., et al. (2013). Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells. J. Clin. Invest. 123, 3876-3888. https://doi.org/10.1172/JCI68557
- Hyde, R.K., Kamikubo, Y., Anderson, S., Kirby, M., Alemu, L., Zhao, L., and Liu, PP. (2010). Cbfb/Runx1 repression-independent blockage of differentiation and accumulation of Csf2rb-expressing cells by Cbfb-MYH11. Blood 115, 1433-1443. https://doi.org/10.1182/blood-2009-06-227413
- Hyde, R.K., Zhao, L., Alemu, L., and Liu, P.P. (2015). Runx1 is required for hematopoietic defects and leukemogenesis in Cbfb-MYH11 knock-in mice. Leukemia 29, 1771-1778. https://doi.org/10.1038/leu.2015.58
- Ito, Y., Bae, S.C., and Chuang, L.S. (2015). The RUNX family: developmental regulators in cancer. Nat. Rev. Cancer 15, 81-95. https://doi.org/10.1038/nrc3877
- Kamikubo, Y. (2018). Genetic compensation of RUNX family transcription factors in leukemia. Cancer Sci. 109, 2358-2363. https://doi.org/10.1111/cas.13664
-
Kamikubo, Y., Hyde, R.K., Zhao, L., Alemu, L., Rivas, C., Garrett, L.J., and Liu, P.P. (2013). The C-terminus of
$CBF\beta$ -SMMHC is required to induce embryonic hematopoietic defects and leukemogenesis. Blood 121, 638-642. https://doi.org/10.1182/blood-2012-06-434688 - Kamikubo, Y., Zhao, L., Wunderlich, M., Corpora, T., Hyde, R.K., Paul, T.A., Kundu, M., Garrett, L., Compton, S., Huang, G., et al. (2010). Accelerated leukemogenesis by truncated CBF beta-SMMHC defective in high-affinity binding with RUNX1. Cancer Cell 17, 455-468. https://doi.org/10.1016/j.ccr.2010.03.022
- Liu, P., Tarle, S.A., Hajra, A., Claxton, D.F., Marlton, P., Freedman, M., Siciliano, M.J., and Collins, F.S. (1993). Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. Science 261, 1041-1044. https://doi.org/10.1126/science.8351518
- Liu, P.P., Hajra, A., Wijmenga, C., and Collins, F.S. (1995). Molecular pathogenesis of the chromosome 16 inversion in the M4Eo subtype of acute myeloid leukemia. Blood 85, 2289-2302. https://doi.org/10.1182/blood.V85.9.2289.bloodjournal8592289
- Lukasik, S.M., Zhang, L., Corpora, T., Tomanicek, S., Li, Y., Kundu, M., Hartman, K., Liu, P.P., Laue, T.M., Biltonen, R.L., et al. (2002). Altered affinity of CBF beta-SMMHC for Runx1 explains its role in leukemogenesis. Nat. Struct. Biol. 9, 674-679. https://doi.org/10.1038/nsb831
- Mitsuda, Y., Morita, K., Maeda, S., Kashiwazaki, G., Taniguchi, J., Bando, T., Hirata, M., Kataoka, T.R., Muto, M., Kaneda, Y., et al. (2018). RUNX1 positively regulates ErbB2/HER2 signaling pathway through modulating SOS1 expression in gastric cancer cells. Sci. Rep. 8, 6423. https://doi.org/10.1038/s41598-018-24969-w
- Morita, K., Maeda, S., Suzuki, K., Kiyose, H., Taniguchi, J., Liu, P.P., Sugiyama, H., Adachi, S., and Kamikubo, Y. (2017b). Paradoxical enhancement of leukemogenesis in acute myeloid leukemia with moderately-attenuated RUNX1 expressions. Blood Adv. 1, 1440-1451. https://doi.org/10.1182/bloodadvances.2017007591
- Morita, K., Noura, M., Tokushige, C., Maeda, S., Kiyose, H., Kashiwazaki, G., Taniguchi, J., Bando, T., Yoshida, K., Ozaki, T., et al. (2017c). Autonomous feedback loop of RUNX1-p53-CBFB in acute myeloid leukemia cells. Sci. Rep. 7, 16604. https://doi.org/10.1038/s41598-017-16799-z
- Morita, K., Suzuki, K., Maeda, S., Matsuo, A., Mitsuda, Y., Tokushige, C., Kashiwazaki, G., Taniguchi, J., Maeda, R., Noura, M., et al. (2017a). Genetic regulation of the RUNX transcription factor family has antitumor effects. J. Clin. Invest. 127, 2815-2828. https://doi.org/10.1172/JCI91788
- Morita, K., Tokushige, C., Maeda, S., Kiyose, H., Noura, M., Iwai, A., Yamada, M., Kashiwazaki, G., Taniguchi, J., Bando, T., et al. (2018). RUNX transcription factors potentially control E-selectin expressions in the vascular niche of mice bone marrow. Blood Adv. 2, 509-515. https://doi.org/10.1182/bloodadvances.2017009324
- Sood, R., Kamikubo, Y., and Liu, P. (2017). Role of RUNX1 in hematological malignancies. Blood 129, 2070-2082. https://doi.org/10.1182/blood-2016-10-687830
- Tahirov, T.H., Inoue-Bungo, T., Morii, H., Fujikawa, A., Sasaki, M., Kimura, K., Shiina, M., Sato, K., Kumasaka, T., Yamamoto, M., et al. (2001). Structural analyses of DNA recognition by the AML1/Runx-1 Runt domain and its allosteric control by CBFbeta. Cell 104, 755-767. https://doi.org/10.1016/S0092-8674(01)00271-9
- Trauger, J.W., Baird, E.E., and Dervan, P.B. (1996). Recognition of DNA by designed ligands at subnanomolar concentrations. Nature 382, 559-561. https://doi.org/10.1038/382559a0
- Warren, A.J., Bravo, J., Williams, R.L., and Rabbitts, T.H. (2000). Structural basis for the heterodimeric interaction between the acute leukaemiaassociated transcription factors AML1 and CBFbeta. EMBO J. 19, 3004-3015. https://doi.org/10.1093/emboj/19.12.3004
- Yan, J., Liu, Y., Lukasik, S.M., Speck, N.A., and Bushweller, J.H. (2004). CBFbeta allosterically regulates the Runx1 Runt domain via a dynamic conformational equilibrium. Nat. Struct. Mol. Biol. 11, 901-906. https://doi.org/10.1038/nsmb819
Cited by
- Runx Transcription Factors in T Cells-What Is Beyond Thymic Development? vol.12, 2020, https://doi.org/10.3389/fimmu.2021.701924
- Expression patterns and prognostic value of RUNX genes in kidney cancer vol.11, pp.1, 2020, https://doi.org/10.1038/s41598-021-94294-2